Strides Pharma Science Limited announced strong financial performance for the second quarter of FY27, reporting a 17% year-on-year increase in revenue to ₹14,297 million. The company also saw an 8.4% rise in EBITDA to ₹2,509 million, crossing the ₹2,500 million mark for the first time in a quarter. Ex-US markets demonstrated robust growth, up 31% YoY.
Strides Pharma Reports Strong Q2 FY27 Performance
Strides Pharma Science Limited has unveiled its consolidated financial results for the quarter ended September 30, 2026, showcasing a significant performance uplift. The company’s revenue for Q2 FY27 stood at ₹14,297 million, marking a substantial 17.1% growth compared to the same period last year (Q2 FY26).
Key Financial Highlights
The company’s Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) saw a healthy increase of 8.4% year-on-year, reaching ₹2,509 million. Notably, this quarter marks the first time Strides Pharma has surpassed the ₹2,500 million EBITDA mark. The EBITDA margin for the quarter was reported at 17.6%. Operational Profit After Tax (PAT) grew by 11.5% to ₹1,358 million, with Operational EPS at ₹14.7. Reported PAT increased by 2.0% to ₹1,341 million, and Reported EPS stood at ₹14.2.
Ex-US Markets Drive Growth
A significant driver of this strong performance was the Ex-US markets, which experienced a remarkable 31% year-on-year growth, contributing ₹6,963 million to the revenue. For the first time, Ex-US markets surpassed the US business in quarterly revenue. The US business also showed positive momentum, growing 9% year-on-year to ₹6,855 million, with 3 products launched during the quarter. This diversification strategy continues to yield positive results for the company.
Management Commentary
Mr. Badree Komandur, MD & Group CEO, commented on the results, stating, “Strides delivered a strong second quarter, with revenue of ₹14,297 million growing ~17% YoY, driven by Ex-US Markets. Our diversification strategy continues to play out, with Ex-US Markets growing 31% YoY to ₹6,963 million and, for the first time, surpassing our US business in quarterly revenue.” He also noted that despite higher input costs due to geopolitical disruptions, the company remains focused on mitigating these pressures through cost optimization. Net Debt increased by ₹2,114 million during H1 FY27 due to an elongated cash-to-cash cycle and higher inventory holding, but the company expects the Net Debt to EBITDA ratio to stabilize by year-end.
Source: BSE
